Novartis to push for diabetes prevention indication with Diovan
This article was originally published in Scrip
Executive Summary
Despite only meeting one co-primary endpoint in the Phase III NAVIGATOR trial of Diovan (valsartan) in patients with impaired glucose tolerance (IGT), Novartis believes that its antihypertensive might be approvable for the prevention of diabetes in this population. Data presented at the American College of Cardiology (ACC) meeting in Atlanta showed that the Swiss company's blockbuster drug reduced the relative risk of developing diabetes by 14%, although it had no effect on patients' cardiovascular health.